These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18414441)

  • 1. Lack of mortality benefit with sevelamer.
    Nolan CR; McCarron DA
    Kidney Int; 2008 May; 73(9):1093; author reply 1093-4. PubMed ID: 18414441
    [No Abstract]   [Full Text] [Related]  

  • 2. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer.
    Nguyen QV; Descombes E
    Kidney Int; 2008 Jan; 73(2):238-9, author reply 239. PubMed ID: 18165813
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The details bedevil DCOR.
    Silver J
    Kidney Int; 2007 Nov; 72(9):1041-3. PubMed ID: 17943149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study probes best choice of drug to reduce phosphate in patients on dialysis.
    Mitka M
    JAMA; 2007 Nov; 298(17):1995-6. PubMed ID: 17986688
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of hyperphosphatemia beyond phosphate.
    Evenepoel P
    Kidney Int; 2007 Mar; 71(5):376-9. PubMed ID: 17315005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?
    Spasovski G; Vanholder R
    Nephrol Dial Transplant; 2011 Apr; 26(4):1442-3; author reply 1443-4. PubMed ID: 21339309
    [No Abstract]   [Full Text] [Related]  

  • 8. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA; Jain AK; Gomes T; Juurlink DN; Mamdani M; Li L; Garg AX
    Am J Kidney Dis; 2011 Feb; 57(2):357-9. PubMed ID: 21251552
    [No Abstract]   [Full Text] [Related]  

  • 12. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Sevelamer reduce mortality by slowing of progression of coronary calcification?
    Badve SV; Magner PO
    Kidney Int; 2007 Jun; 71(12):1328-9. PubMed ID: 17554361
    [No Abstract]   [Full Text] [Related]  

  • 14. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer reduces the efficacy of many other drugs.
    Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J
    Nefrologia; 2008; 28 Suppl 5():53-7. PubMed ID: 18847421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer and extension studies.
    McFarlane PA
    Kidney Int; 2007 Jul; 72(2):225-6. PubMed ID: 17625584
    [No Abstract]   [Full Text] [Related]  

  • 19. Levothyroxine and sevelamer: listen to the patient.
    Granata A; Floccari F; Gallieni M
    Endocr Pract; 2011; 17(6):961-2. PubMed ID: 22299156
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.